Phenotypes associated with this allele

• Allele Symbol: Prkcq^tm1Litt
• Allele Name: targeted mutation 1, Dan Littman
• Allele ID: MGI:2664379
• Summary: 13 genotypes

Jump to	Allelic Composition	Genetic Background	Genotype ID
hm1	Prkcq^tm1Litt/Prkcq^tm1Litt	B6.129P2-Prkcq^tm1Litt	MGI:4843311
hm2	Prkcq^tm1Litt/Prkcq^tm1Litt	either: (involves: 129/Sv * 129P2/OlaHsd) or (involves: 129P2/OlaHsd * C57BL/6)	MGI:4843459
hm3	Prkcq^tm1Litt/Prkcq^tm1Litt	involves: 129P2/OlaHsd	MGI:2664510
hm4	Prkcq^tm1Litt/Prkcq^tm1Litt	involves: 129P2/OlaHsd * C57BL/6	MGI:4843396
hm5	Prkcq^tm1Litt/Prkcq^tm1Litt	involves: 129P2/OlaHsd * C57BL/6J	MGI:4843468
ht6	Prkcq^tm1Litt/Prkcq^+	B6.129P2-Prkcq^tm1Litt	MGI:4843312
cn7	Prkcq^tm1Litt/Prkcq^tm1Litt Tg(TcrLCMV)327Sdz/0	involves: 129P2/OlaHsd * C57BL/6 * DBA/2	MGI:4843384
cx8	Crb1^rd8/Crb1^rd8 Prkcq^tm1Litt/Prkcq^tm1Litt	B6.129P2-Prkcq^tm1Litt	MGI:5904137
cx9	Prkcq^tm1Litt/Prkcq^tm1Litt Tg(DO11.10)10Dlo/0	involves: 129 * BALB/c * C3H * C57BL/6	MGI:4843460
cx10	Prkcq^tm1Litt/Prkcq^tm1Litt Tcra^tm1Mom/Tcra^tm1Mom	involves: 129P2/OlaHsd * 129S2/SvPas	MGI:4843514
cx11	Prkcq^tm1Litt/Prkcq^tm1Litt Tg(LCKprBCL2L1)12Sjk/0	involves: 129P2/OlaHsd * C57BL/6	MGI:4843486
cx12	Prkcq^tm1Litt/Prkcq^tm1Litt Tg(Lck-Notch3)#Issc/0	involves: 129P2/OlaHsd * C57BL/6 * DBA/2	MGI:4843446
cx13	Prkch^tm1.2Gasc/Prkch^tm1.2Gasc Prkcq^tm1Litt/Prkcq^tm1Litt	involves: 129P2/OlaHsd * C57BL/6 * FVB/N * SJL	MGI:5431088

Genotype
MGI:4843311

hm1

• Allelic Composition: Prkcq^tm1Litt/Prkcq^tm1Litt
• Genetic Background: B6.129P2-Prkcq^tm1Litt

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

pigmentation

decreased eye pigmentation ( J:237977 )

immune system

immune system phenotype ( J:94285 )

N • mice exhibit normal lung inflammation driven by Th1 cytokines

decreased T cell proliferation ( J:94285 )

• in mice immunized with ovalbumin in alum

• however, proliferation of T cells in mice stimulated with ovalbumin and complete Freund's adjuvant is normal

decreased splenocyte proliferation ( J:129421 )

• on day 14, but not day 21, following induction of experimental autoimmune encephalomyelitis (EAE)

abnormal T-helper 1 cell differentiation ( J:94285 )

• Th1 stimulated T cells exhibit delayed differentiation and accumulation compared with similarly treated wild-type cells

• however, Th1 cytokine production is normal in antigen airway challenge

abnormal CD4-positive, alpha-beta T cell physiology ( J:94285 )

• accumulation of antigen-induced CD4 cells in lung draining lymph nodes during Th2 lung inflammation is decreased compared to in similarly treated wild-type mice

abnormal T-helper 2 physiology ( J:94285 )

• following ovalbumin challenge, production of Th2 cytokines (Il4, Il5, and Il13) compared to in similarly treated wild-type mice

• stimulated CD4 T cells exhibit impaired early Th2 and Th1 differentiation compared with similarly treated wild-type cells

decreased interferon-gamma secretion ( J:94285 , J:129421 )

• from CD4 T cells stimulated by anti-CD3, anti-CD28 antibodies but not when IL2 was present (J:94285)

• from CD4 T cells from mice stimulated subcutaneously with ovalbumin and complete Freund's adjuvant (J:94285)

• following induction of experimental autoimmune encephalomyelitis (EAE) (J:129421)

decreased interleukin-13 secretion ( J:94285 )

• in the bronchoalveolar lavage fluid of ovalbumin challenged mice

decreased interleukin-17 secretion ( J:129421 )

• following induction of experimental autoimmune encephalomyelitis (EAE), splenocytes produce less IL17 compared to in similarly treated wild-type mice

• IL23-stimulated spleen cultures produce less IL17 compared with similarly treated wild-type cultures

• however, ovalbumin-stimulated splenocytes exhibit normal IL17 production

decreased interleukin-2 secretion ( J:94285 , J:129421 )

• from CD4 T cells from mice stimulated subcutaneously with ovalbumin and complete Freund's adjuvant (J:94285)

• from splenocytes on day 14, but not day 21, following induction of experimental autoimmune encephalomyelitis (EAE) (J:129421)

decreased interleukin-4 secretion ( J:94285 , J:129421 )

• in the bronchoalveolar lavage fluid of ovalbumin challenged mice (J:94285)

• from CD4 T cells stimulated by anti-CD3, anti-CD28 antibodies with or without IL2 (J:94285)

• from CD4 T cells from mice stimulated with ovalbumin in alum (J:94285)

• from splenocytes on day 14, but not day 21, following induction of experimental autoimmune encephalomyelitis (EAE) (J:129421)

decreased interleukin-5 secretion ( J:94285 )

• in the bronchoalveolar lavage fluid of ovalbumin challenged mice

• from CD4 T cells from mice stimulated with ovalbumin in alum

decreased susceptibility to experimental autoimmune encephalomyelitis ( J:129421 )

• mice treated with MOG35-55 are completely resistance to experimental autoimmune encephalomyelitis (EAE) induction (reduced inflammation, no demyelinating lesions, decreased production of Th1 cytokines IFN-gamma, IL2, and IL4, and IL17 production) compared with similarly treated wild-type mice

vision/eye

decreased eye pigmentation ( J:237977 )

abnormal ocular fundus morphology ( J:237977 )

• by 10 months of age there are large confluent areas of depigmentation in addition to the retinal detachments

retina degeneration ( J:237977 )

retina detachment ( J:237977 )

• by 10 months of age

respiratory system

decreased airway responsiveness ( J:94285 )

• mice exhibit attenuated methacholine sensitivity compared with similarly treated wild-type mice

nervous system

abnormal nervous system development ( J:96919 )

• developmental dennervation of polyinnervated neuromuscular junctions is delayed compared to in wild-type mice

abnormal neuromuscular synapse morphology ( J:96919 )

• in a twitch assay, PMA-treated muscles even with normal nerves and glia in the preparation fail to exhibit synapse loss unlike similarly treated wild-type muscles

• in a twitch assay, PMA-treated neurons with normal muscles and glia in the preparation fail to exhibit synapse loss unlike similarly treated wild-type muscles

abnormal endplate potential ( J:96919 )

• following stimulation, myotubes fail to exhibit a decrement in endplate potential (EPP) amplitude unlike in similarly treated wild-type cells

• following PMA treatment, muscles with wild-type nerves and glia or ventral spinal cord nerves with wild-type muscles and glia fail to exhibit a decrease in endplate amplitude compared with similarly treated wild-type muscles

• however, ventral spinal cord neurons treated with PMA and TTX exhibit a normal decrease in EPP amplitude

homeostasis/metabolism

decreased physiological sensitivity to xenobiotic ( J:94285 )

• mice exhibit attenuated methacholine sensitivity compared with similarly treated wild-type mice

• ovalbumin-treated mice exhibit a reduction in accumulation of leukocytes, including eosinophils and lymphocytes, in bronchoalveolar lavage fluid and lung tissue, relatively normal bronchial epithelium, reduced mucus, and reduced Th2 cytokines compared with similarly treated wild-type mice

hematopoietic system

decreased T cell proliferation ( J:94285 )

• in mice immunized with ovalbumin in alum

• however, proliferation of T cells in mice stimulated with ovalbumin and complete Freund's adjuvant is normal

decreased splenocyte proliferation ( J:129421 )

• on day 14, but not day 21, following induction of experimental autoimmune encephalomyelitis (EAE)

abnormal T-helper 1 cell differentiation ( J:94285 )

• Th1 stimulated T cells exhibit delayed differentiation and accumulation compared with similarly treated wild-type cells

• however, Th1 cytokine production is normal in antigen airway challenge

abnormal CD4-positive, alpha-beta T cell physiology ( J:94285 )

• accumulation of antigen-induced CD4 cells in lung draining lymph nodes during Th2 lung inflammation is decreased compared to in similarly treated wild-type mice

abnormal T-helper 2 physiology ( J:94285 )

• following ovalbumin challenge, production of Th2 cytokines (Il4, Il5, and Il13) compared to in similarly treated wild-type mice

• stimulated CD4 T cells exhibit impaired early Th2 and Th1 differentiation compared with similarly treated wild-type cells

cellular

decreased T cell proliferation ( J:94285 )

• in mice immunized with ovalbumin in alum

• however, proliferation of T cells in mice stimulated with ovalbumin and complete Freund's adjuvant is normal

decreased splenocyte proliferation ( J:129421 )

• on day 14, but not day 21, following induction of experimental autoimmune encephalomyelitis (EAE)

Mouse Models of Human Disease		DO ID	OMIM ID(s)	Ref(s)
retinal detachment		DOID:5327		J:237977

Genotype
MGI:4843459

hm2

• Allelic Composition: Prkcq^tm1Litt/Prkcq^tm1Litt
• Genetic Background: either: (involves: 129/Sv * 129P2/OlaHsd) or (involves: 129P2/OlaHsd * C57BL/6)

immune system

decreased T cell apoptosis ( J:141930 )

• induced by Fas or staphylococcal enterotoxin B challenge

• however, IL2 restores Fas-mediated apoptosis

decreased T cell proliferation ( J:141930 )

• following exposure to staphylococcal enterotoxin B, expansion of Vbeta8+CD4+ T cells is reduced compared to in similarly treated wild-type mice

abnormal response to infection ( J:141930 )

• following exposure to staphylococcal enterotoxin B, expansion and deletion of Vbeta8+CD4+ T cells is reduced compared to in similarly treated wild-type mice

hematopoietic system

decreased T cell apoptosis ( J:141930 )

• induced by Fas or staphylococcal enterotoxin B challenge

• however, IL2 restores Fas-mediated apoptosis

decreased T cell proliferation ( J:141930 )

• following exposure to staphylococcal enterotoxin B, expansion of Vbeta8+CD4+ T cells is reduced compared to in similarly treated wild-type mice

cellular

decreased T cell apoptosis ( J:141930 )

• induced by Fas or staphylococcal enterotoxin B challenge

• however, IL2 restores Fas-mediated apoptosis

decreased T cell proliferation ( J:141930 )

• following exposure to staphylococcal enterotoxin B, expansion of Vbeta8+CD4+ T cells is reduced compared to in similarly treated wild-type mice

Genotype
MGI:2664510

hm3

• Allelic Composition: Prkcq^tm1Litt/Prkcq^tm1Litt
• Genetic Background: involves: 129P2/OlaHsd

immune system

immune system phenotype ( J:123989 )

N • mice mount a normal immune response to LCMV

N • T cells exhibitnormal CD28 costimulation

N • mice exhibit normal isotype switching and germinal center formation

abnormal T cell activation ( J:83922 )

• TCR-initiated NF-kappaB activation was absent in mature T lymphocytes, but intact in developing thymocytes

decreased T cell proliferation ( J:83922 , J:123989 )

• proliferation of T cells after stimulation with anti-CD3 mAb with or without anti-CD28 stimulation is reduced by more than 20-fold compared to wild-type T cells (J:83922)

• proliferation of T cells after anti-CD28 plus TPA (12-O-tetradacanoylphorbol-13-acetate) stimulation is reduced (J:83922)

• proliferation of T cells is reduced in mixed lymphocyte reactions (J:83922)

• T cell proliferation in response to a T-cell-dependent antigen, keyhole limpet haemocyanin (KLH) is impaired (J:83922)

• in response to anti-CD3 stimulation (J:123989)

• however, CD28 costimulation is normal (J:123989)

decreased interleukin-2 secretion ( J:83922 )

• splenic T cell stimulated with anti-CD3 and anti-CD28 show a large reduction in the level of secreted IL-2

hematopoietic system

abnormal T cell activation ( J:83922 )

• TCR-initiated NF-kappaB activation was absent in mature T lymphocytes, but intact in developing thymocytes

decreased T cell proliferation ( J:83922 , J:123989 )

• proliferation of T cells after stimulation with anti-CD3 mAb with or without anti-CD28 stimulation is reduced by more than 20-fold compared to wild-type T cells (J:83922)

• proliferation of T cells after anti-CD28 plus TPA (12-O-tetradacanoylphorbol-13-acetate) stimulation is reduced (J:83922)

• proliferation of T cells is reduced in mixed lymphocyte reactions (J:83922)

• T cell proliferation in response to a T-cell-dependent antigen, keyhole limpet haemocyanin (KLH) is impaired (J:83922)

• in response to anti-CD3 stimulation (J:123989)

• however, CD28 costimulation is normal (J:123989)

cellular

decreased T cell proliferation ( J:83922 , J:123989 )

• proliferation of T cells after stimulation with anti-CD3 mAb with or without anti-CD28 stimulation is reduced by more than 20-fold compared to wild-type T cells (J:83922)

• proliferation of T cells after anti-CD28 plus TPA (12-O-tetradacanoylphorbol-13-acetate) stimulation is reduced (J:83922)

• proliferation of T cells is reduced in mixed lymphocyte reactions (J:83922)

• T cell proliferation in response to a T-cell-dependent antigen, keyhole limpet haemocyanin (KLH) is impaired (J:83922)

• in response to anti-CD3 stimulation (J:123989)

• however, CD28 costimulation is normal (J:123989)

Genotype
MGI:4843396

hm4

• Allelic Composition: Prkcq^tm1Litt/Prkcq^tm1Litt
• Genetic Background: involves: 129P2/OlaHsd * C57BL/6

homeostasis/metabolism

abnormal glucose homeostasis ( J:92834 )

• lipid infusion does not alter insulin sensitivity, muscular and brown fat adipose tissue glucose uptake, or whole-body and muscular metabolic flux, including glycolysis and glycogen synthesis, unlike in similarly treated wild-type mice

increased insulin sensitivity ( J:92834 )

• lipid infused mice do not exhibit a decrease in insulin sensitivity compared with similarly treated wild-type mice

immune system

immune system phenotype ( J:141128 )

N • mice exhibit normal regulatory T cells-mediated inhibition of T cell activation, IL2-induced expansion of regulatory T cells, and regulatory T cells TGF-beta production

increased T cell apoptosis ( J:141128 )

• following CD3 and CD28 stimulation, T cell apoptosis is accelerated compared to in similarly treated wild-type cells

decreased T cell proliferation ( J:186080 )

• when stimulated by anti-CD3 antibodies or antigens (in vitro and in vivo)

decreased DN1 thymic pro-T cell number ( J:186080 )

abnormal positive T cell selection ( J:186080 )

• mildly impaired

abnormal effector T cell morphology ( J:186080 )

• the ratio of CD4 to CD8 T cells is lower than in wild-type mice

decreased CD4-positive, alpha-beta T cell number ( J:186080 )

decreased CD8-positive, alpha-beta T cell number ( J:186080 )

decreased NK T cell number ( J:141128 )

adipose tissue

abnormal adipocyte glucose uptake ( J:92834 )

• lipid infusion does not alter brown adipose tissue glucose uptake unlike in wild-type mice

• however, white adipose tissue glucose uptake is similarly decreased following lipid infusion as in wild-type mice

muscle

abnormal muscle cell glucose uptake ( J:92834 )

• lipid infusion does not alter muscle glucose uptake unlike in wild-type mice

hematopoietic system

increased T cell apoptosis ( J:141128 )

• following CD3 and CD28 stimulation, T cell apoptosis is accelerated compared to in similarly treated wild-type cells

decreased T cell proliferation ( J:186080 )

• when stimulated by anti-CD3 antibodies or antigens (in vitro and in vivo)

decreased DN1 thymic pro-T cell number ( J:186080 )

abnormal positive T cell selection ( J:186080 )

• mildly impaired

abnormal effector T cell morphology ( J:186080 )

• the ratio of CD4 to CD8 T cells is lower than in wild-type mice

decreased CD4-positive, alpha-beta T cell number ( J:186080 )

decreased CD8-positive, alpha-beta T cell number ( J:186080 )

decreased NK T cell number ( J:141128 )

cellular

abnormal adipocyte glucose uptake ( J:92834 )

• lipid infusion does not alter brown adipose tissue glucose uptake unlike in wild-type mice

• however, white adipose tissue glucose uptake is similarly decreased following lipid infusion as in wild-type mice

increased T cell apoptosis ( J:141128 )

• following CD3 and CD28 stimulation, T cell apoptosis is accelerated compared to in similarly treated wild-type cells

decreased T cell proliferation ( J:186080 )

• when stimulated by anti-CD3 antibodies or antigens (in vitro and in vivo)

abnormal muscle cell glucose uptake ( J:92834 )

• lipid infusion does not alter muscle glucose uptake unlike in wild-type mice

endocrine/exocrine glands

decreased DN1 thymic pro-T cell number ( J:186080 )

Genotype
MGI:4843468

hm5

• Allelic Composition: Prkcq^tm1Litt/Prkcq^tm1Litt
• Genetic Background: involves: 129P2/OlaHsd * C57BL/6J

hematopoietic system

abnormal platelet physiology ( J:144254 )

• platelets exhibit reduced adhesion and degree of filopodia generation on fibrinogen-coated cover slips compared with wild-type cells

• in mice, platelet exhibit a different distribution of filopodial number compared with wild-type cells

• however, platelet adhesion and spreading on CRP or collagen are normal

abnormal platelet activation ( J:144254 )

• CRP platelet activation is enhanced compared to in wild-type cells

increased platelet aggregation ( J:144254 )

• anti-coagulated blood passed over a collagen-coated cover slips forms larger thrombi compared with similarly treated wild-type blood

abnormal platelet dense granule physiology ( J:144254 )

• GPVI-dependent alpha-granule secretion is enhanced compared to in wild-type cells

• however, ATP secretion induced by CRP or collagen is normal

homeostasis/metabolism

abnormal platelet physiology ( J:144254 )

• platelets exhibit reduced adhesion and degree of filopodia generation on fibrinogen-coated cover slips compared with wild-type cells

• in mice, platelet exhibit a different distribution of filopodial number compared with wild-type cells

• however, platelet adhesion and spreading on CRP or collagen are normal

abnormal platelet activation ( J:144254 )

• CRP platelet activation is enhanced compared to in wild-type cells

increased platelet aggregation ( J:144254 )

• anti-coagulated blood passed over a collagen-coated cover slips forms larger thrombi compared with similarly treated wild-type blood

abnormal platelet dense granule physiology ( J:144254 )

• GPVI-dependent alpha-granule secretion is enhanced compared to in wild-type cells

• however, ATP secretion induced by CRP or collagen is normal

Genotype
MGI:4843312

ht6

• Allelic Composition: Prkcq^tm1Litt/Prkcq⁺
• Genetic Background: B6.129P2-Prkcq^tm1Litt

nervous system

abnormal neuromuscular synapse morphology ( J:96919 )

• PMA-treated neurons with normal muscles and glia in the preparation fail to exhibit synapse loss unlike similarly treated wild-type muscles that is not as severe as in samples from homozygotes

Genotype
MGI:4843384

cn7

• Allelic Composition: Prkcq^tm1Litt/Prkcq^tm1Litt; Tg(TcrLCMV)327Sdz/0
• Genetic Background: involves: 129P2/OlaHsd * C57BL/6 * DBA/2

immune system

decreased T cell proliferation ( J:123989 )

• CD8 T cells require 10- to 100-fold more antigen (gp33 peptide) to induce the same amount of proliferation as cells from Tg(TcrLCMV)327Sdz mice

• however, addition of IL2 partially restores CD8 T cell proliferation in response to gp33 peptide

decreased splenocyte proliferation ( J:123989 )

• in mice treated gp33 peptide

decreased cytotoxic T cell cytolysis ( J:123989 )

• after 3 days, cytotoxic T lymphocyte (CTL) activation in mice treated with gp33 peptide is decreased compared to in Tg(TcrLCMV)327Sdz mice

• splenocytes exposed to gp33 exhibit impaired CTL activation compared with similarly treated cells from Tg(TcrLCMV)327Sdz mice

• however, CTL activation in mice treated with gp33 peptide is normal at day 1 and treatment with IL2 restores CTL in splenocytes

abnormal T cell anergy ( J:123989 )

• cytotoxic T lymphocyte anergy is induced in mice treated with gp33 peptide unlike in similarly treated Tg(TcrLCMV)327Sdz mice

hematopoietic system

decreased T cell proliferation ( J:123989 )

• CD8 T cells require 10- to 100-fold more antigen (gp33 peptide) to induce the same amount of proliferation as cells from Tg(TcrLCMV)327Sdz mice

• however, addition of IL2 partially restores CD8 T cell proliferation in response to gp33 peptide

decreased splenocyte proliferation ( J:123989 )

• in mice treated gp33 peptide

decreased cytotoxic T cell cytolysis ( J:123989 )

• after 3 days, cytotoxic T lymphocyte (CTL) activation in mice treated with gp33 peptide is decreased compared to in Tg(TcrLCMV)327Sdz mice

• splenocytes exposed to gp33 exhibit impaired CTL activation compared with similarly treated cells from Tg(TcrLCMV)327Sdz mice

• however, CTL activation in mice treated with gp33 peptide is normal at day 1 and treatment with IL2 restores CTL in splenocytes

cellular

decreased T cell proliferation ( J:123989 )

• CD8 T cells require 10- to 100-fold more antigen (gp33 peptide) to induce the same amount of proliferation as cells from Tg(TcrLCMV)327Sdz mice

• however, addition of IL2 partially restores CD8 T cell proliferation in response to gp33 peptide

decreased splenocyte proliferation ( J:123989 )

• in mice treated gp33 peptide

Genotype
MGI:5904137

cx8

• Allelic Composition: Crb1^rd8/Crb1^rd8; Prkcq^tm1Litt/Prkcq^tm1Litt
• Genetic Background: B6.129P2-Prkcq^tm1Litt

pigmentation

decreased eye pigmentation ( J:237977 )

vision/eye

decreased eye pigmentation ( J:237977 )

abnormal ocular fundus morphology ( J:237977 )

• by 10 months of age there are large confluent areas of depigmentation in addition to the retinal detachments

retina degeneration ( J:237977 )

retina detachment ( J:237977 )

• by 10 months of age

Genotype
MGI:4843460

cx9

• Allelic Composition: Prkcq^tm1Litt/Prkcq^tm1Litt; Tg(DO11.10)10Dlo/0
• Genetic Background: involves: 129 * BALB/c * C3H * C57BL/6

immune system

decreased T cell apoptosis ( J:141930 )

• induced by Fas

cellular

decreased T cell apoptosis ( J:141930 )

• induced by Fas

hematopoietic system

decreased T cell apoptosis ( J:141930 )

• induced by Fas

Genotype
MGI:4843514

cx10

• Allelic Composition: Prkcq^tm1Litt/Prkcq^tm1Litt; Tcra^tm1Mom/Tcra^tm1Mom
• Genetic Background: involves: 129P2/OlaHsd * 129S2/SvPas

immune system

immune system phenotype ( J:135589 )

N • unlike Tcra^tm1Mom homozygotes, mice do not develop colitis

decreased T cell proliferation ( J:135589 )

• colonic T cells exhibit decreased proliferation compared to in Tcra^tm1Mom homozygotes without altering the apoptotic response

decreased interleukin-4 secretion ( J:135589 )

• IL4 is not detected in colonic T cells unlike in Tcra^tm1Mom homozygotes

digestive/alimentary system

digestive/alimentary phenotype ( J:135589 )

N • unlike Tcra^tm1Mom homozygotes, mice do not develop colitis

hematopoietic system

decreased T cell proliferation ( J:135589 )

• colonic T cells exhibit decreased proliferation compared to in Tcra^tm1Mom homozygotes without altering the apoptotic response

cellular

decreased T cell proliferation ( J:135589 )

• colonic T cells exhibit decreased proliferation compared to in Tcra^tm1Mom homozygotes without altering the apoptotic response

Genotype
MGI:4843486

cx11

• Allelic Composition: Prkcq^tm1Litt/Prkcq^tm1Litt; Tg(LCKprBCL2L1)12Sjk/0
• Genetic Background: involves: 129P2/OlaHsd * C57BL/6

immune system

immune system phenotype ( J:141128 )

N • apoptosis of CD3 and CD28 stimulated T cells is normal

decreased NK T cell number ( J:141128 )

hematopoietic system

decreased NK T cell number ( J:141128 )

Genotype
MGI:4843446

cx12

• Allelic Composition: Prkcq^tm1Litt/Prkcq^tm1Litt; Tg(Lck-Notch3)#Issc/0
• Genetic Background: involves: 129P2/OlaHsd * C57BL/6 * DBA/2

mortality/aging

extended life span ( J:96010 )

• compared with Tg(lck-Notch3)#Issc mice

premature death ( J:96010 )

• 35% of mice die prior to 20 weeks of age

• of mice that survive beyond 20 weeks, 50% die over 30 weeks of age and 20% survive at 50 weeks of age

neoplasm

decreased lymphoma incidence ( J:96010 )

• 40% of mice that survive beyond 20 weeks of age exhibit lymphoproliferative disease (enlarged upper mediastium and 2- to 3-fold increase in spleen size and weight) compared with 95% of Tg(lck-Notch3)#Issc mice

immune system

enlarged spleen ( J:96010 )

• 2- to 3-fold in 40% of mice that survive beyond 20 weeks of age

increased spleen weight ( J:96010 )

• 2- to 3-fold in 40% of mice that survive beyond 20 weeks of age

growth/size/body

enlarged chest ( J:96010 )

• 40% of mice that survive beyond 20 weeks of age exhibit enlarged upper mediastium compared with wild-type mice

enlarged spleen ( J:96010 )

• 2- to 3-fold in 40% of mice that survive beyond 20 weeks of age

increased spleen weight ( J:96010 )

• 2- to 3-fold in 40% of mice that survive beyond 20 weeks of age

hematopoietic system

enlarged spleen ( J:96010 )

• 2- to 3-fold in 40% of mice that survive beyond 20 weeks of age

increased spleen weight ( J:96010 )

• 2- to 3-fold in 40% of mice that survive beyond 20 weeks of age

Genotype
MGI:5431088

cx13

• Allelic Composition: Prkch^tm1.2Gasc/Prkch^tm1.2Gasc; Prkcq^tm1Litt/Prkcq^tm1Litt
• Genetic Background: involves: 129P2/OlaHsd * C57BL/6 * FVB/N * SJL

immune system

immune system phenotype ( J:186080 )

N • unlike in either single homozygote, the ratio of CD4 to CD8 T cells is normal

decreased T cell proliferation ( J:186080 )

• mildly impaired when stimulated by anti-CD3 antibodies

abnormal positive T cell selection ( J:186080 )

• strongly impaired

decreased double-negative T cell number ( J:186080 )

• greater than in single knock-out mice

decreased DN1 thymic pro-T cell number ( J:186080 )

• greater than in single knock-out mice

decreased DN4 thymocyte number ( J:186080 )

• greater than in single knock-out mice

decreased double-positive T cell number ( J:186080 )

• greater than in single knock-out mice

decreased CD4-positive, alpha-beta T cell number ( J:186080 )

• greater than in single knock-out mice

decreased CD8-positive, alpha-beta T cell number ( J:186080 )

• greater than in single knock-out mice

hematopoietic system

decreased T cell proliferation ( J:186080 )

• mildly impaired when stimulated by anti-CD3 antibodies

abnormal positive T cell selection ( J:186080 )

• strongly impaired

decreased double-negative T cell number ( J:186080 )

• greater than in single knock-out mice

decreased DN1 thymic pro-T cell number ( J:186080 )

• greater than in single knock-out mice

decreased DN4 thymocyte number ( J:186080 )

• greater than in single knock-out mice

decreased double-positive T cell number ( J:186080 )

• greater than in single knock-out mice

decreased CD4-positive, alpha-beta T cell number ( J:186080 )

• greater than in single knock-out mice

decreased CD8-positive, alpha-beta T cell number ( J:186080 )

• greater than in single knock-out mice

endocrine/exocrine glands

decreased DN1 thymic pro-T cell number ( J:186080 )

• greater than in single knock-out mice

decreased DN4 thymocyte number ( J:186080 )

• greater than in single knock-out mice

cellular

decreased T cell proliferation ( J:186080 )

• mildly impaired when stimulated by anti-CD3 antibodies